参考文献/References:
[1] Jones C, Perryman L, Hargrave D. Paediatric and adult malignant glioma: close relatives or distant cousins [J]? Nat Rev Clin Oncol, 2012, 9(7): 400-413.
[2] Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials[J]. Lancet Oncol,2006, 7(3): 241-248.
[3] Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma [J]. Nature, 2012, 482(7384): 226-231.
[4] Wu G, Broniscer A, McEachron TA, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas [J]. Nat Genet, 2012, 44(3): 251-253.
[5] Castel D, Philippe C, Calmon R, et al. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuseintrinsic pontine gliomas with different prognosis and phe-notypes [J]. Acta Neuropathol, 2015, 130(6): 815-827.
[6] Fontebasso AM, Papillon-Cavanagh S, Schwartzentruber J, et al. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma [J]. Nat Genet, 2014, 46(5): 462-466.
[7] Mackay A, Burford A, Carvalho D, et al. Integrated molecu-lar meta-analysis of 1, 000 pediatric high-grade and diffuseintrinsic pontine glioma [J]. Cancer Cell, 2017, 32(4): 520-537.
[8] Taylor KR, Mackay A, Truffaux N, et al. Recurrent activa-ting ACVR1 mutations in diffuse intrinsic pontine glioma [J]. Nat Genet, 2014, 46(5): 457-461.
[9] Wu G, Diaz AK, Paugh BS, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brain-stem high-grade glioma [J]. Nat Genet, 2014, 46: 444-450.
[10] Cao R, Zhang Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3 [J]. Curr Opin Genet Dev, 2004, 14(2): 155-164.（下转第136页）（上接第132页）
[11] Tie F, Banerjee R, Stratton CA, et al. CBP-mediated acety-lation of histone H3 lysine 27 antagonizes Drosophila Polycomb silencing [J]. Development, 2009, 136(18): 3131-3141.
[12] Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma [J]. Cancer Cell, 2012, 22(4): 425-437.
[13] Lewis PW, Müller MM, Koletsky MS, et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma [J]. Science, 2013, 340(6134): 857-861.
[14] Chan KM, Han J, Fang D, et al. A lesson learned from the H3.3K27M mutation found in pediatric glioma: a new approach to the study of the function of histone modifica-tions in vivo [J]. Cell Cycle, 2013, 12(16): 2546-2552.
[15] Piunti A, Hashizume R, Morgan MA, et al. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas [J]. Nat Med, 2017, 23(4): 493-500.
[16] Chan KM, Fang D, Gan H, et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylationand gene expression [J]. Genes Dev, 2013, 27(9): 985-990.
[17] Bender S, Tang Y, Lindroth AM, et al. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expre-ssion in K27M mutant pediatric high-grade gliomas [J]. Cancer Cell, 2013, 24(5): 660-672.
[18] Zarghooni M, Bartels U, Lee E, et al. Whole-genome profi-ling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets [J]. J Clin Oncol, 2010, 28(8): 1337-1344.
[19] Mohammad F, Weissmann S, Leblanc B, et al. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas [J]. Nat Med, 2017, 23(4): 483-492.
[20] Hashizume R, Andor N, Ihara Y, et al. Pharmacologic inhi-bition of histone demethylation as a therapy for pediatric brainstem glioma [J]. Nat Med, 2014, 20(12): 1394-1396.
[21] Grasso CS, Tang Y, Truffaux N, et al. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma [J]. Nat Med, 2015, 21(6): 555-559.